Filament Health Corp Total Liabilities
Filament Health Corp total liabilities. Based on the latest financial reports, Filament Health Corp (FH) has total liabilities worth CA$1.94 Million CAD (≈ $1.40 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Filament Health Corp to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Filament Health Corp (2020–2024)
Total liabilities of Filament Health Corp from 2020 to 2024. This chart illustrates how Filament Health Corp's total liabilities have evolved over time, based on quarterly financial data. Explore Filament Health Corp (FH) long-term investment share to see how much of total assets are deployed in long-term investments.
Filament Health Corp Competitors by Total Liabilities
The table below lists competitors of Filament Health Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dotdigital Group Plc
LSE:DOTD
|
UK | GBX33.54 Million |
|
Hitek Global Inc.
NASDAQ:HKIT
|
USA | $6.57 Million |
|
Westar Resources Ltd
AU:WSR
|
Australia | AU$114.20K |
|
Starbreeze AB (publ)
ST:STAR-A
|
Sweden | Skr116.45 Million |
|
Prominence Energy Ltd
AU:PRM
|
Australia | AU$88.42K |
|
Lifeclean International AB
ST:LCLEAN
|
Sweden | Skr40.98 Million |
|
Somero Enterprise Inc
LSE:SOM
|
UK | GBX12.84 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Filament Health Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Filament Health Corp asset portfolio.
Liquidity & Leverage Metrics
Filament Health Corp Total Liabilities Ratios Explained
Filament Health Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Filament Health Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Filament Health Corp (2020–2024)
The table below shows the annual total liabilities of Filament Health Corp from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$1.66 Million ≈ $1.20 Million |
-46.02% |
| 2023-12-31 | CA$3.08 Million ≈ $2.23 Million |
+99.35% |
| 2022-12-31 | CA$1.55 Million ≈ $1.12 Million |
+19.99% |
| 2021-12-31 | CA$1.29 Million ≈ $932.83K |
+1798.69% |
| 2020-12-31 | CA$67.92K ≈ $49.13K |
-- |
About Filament Health Corp
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company's leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provide… Read more